Metabolic

Intervention Reduces CVD Risk in Older Adults With Metabolic Syndrome

Intervention Reduces CVD Risk in Older Adults With Metabolic Syndrome

By

A 12-month intensive lifestyle intervention including an energy-restricted Mediterranean diet, increased physical activity, and behavioral support for overweight/obese patients was found to be beneficial in decreasing adiposity and cardiovascular events.

Coronary Artery Calcium Associated With ASCVD Events in Familial Hypercholesterolemia

Coronary Artery Calcium Associated With ASCVD Events in Familial Hypercholesterolemia

By

CAC was found to be independently associated with ASCVD events in familiar hypercholesterolemia treated with standard lipid lowering therapy.

Elevated Triglyceride Levels Affect Glycemic Control in Type 2 Diabetes

Elevated Triglyceride Levels Affect Glycemic Control in Type 2 Diabetes

By

Reducing triglyceride levels in patients with type 2 diabetes may help them attain more optimal glycemic control.

Hyperlipidemia Screening Rates Low Among Patients With Rheumatoid Arthritis

Hyperlipidemia Screening Rates Low Among Patients With Rheumatoid Arthritis

Primary lipid screening rates were suboptimal among patients with rheumatoid arthritis.

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

By

The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

By

The American College of Cardiology published an expert consensus statement regarding decision considerations for novel cardiovascular risk reduction therapies in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Onset of Musculoskeletal Adverse Events Varies Between Statins

Onset of Musculoskeletal Adverse Events Varies Between Statins

The onset of musculoskeletal adverse events during statin monotherapy is significantly faster with use of atorvastatin and rosuvastatin versus simvastatin.

Simvastatin Improves Platelet Activation Markers in Primary Hypercholesterolemia

Simvastatin Improves Platelet Activation Markers in Primary Hypercholesterolemia

By

In patients with primary hypercholesterolemia, short-term treatment with simvastatin improved the lipid profile and exerted a beneficial effect on a wide range of proatherogenic and prothrombotic parameters.

Total CV Event Reduction More Effectively Assesses Alirocumab Efficacy After ACS

Total CV Event Reduction More Effectively Assesses Alirocumab Efficacy After ACS

By

Total cardiovascular event reduction may represent a more comprehensive metric to assess alirocumab clinical efficacy after acute coronary syndrome.

Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

By

AKCEA-APO(a)-LRX is efficient and safe in patients with established cardiovascular disease and elevated levels of lipoprotein(a).

AHA/ACC Release Updated Guidelines for Cholesterol Management

AHA/ACC Release Updated Guidelines for Cholesterol Management

By

Updated cholesterol guidelines offer more personalized cardiovascular disease risk assessment.

Omega-3 Fatty Acids Reduce MACE in Mild Hypertriglyceridemia

Omega-3 Fatty Acids Reduce MACE in Mild Hypertriglyceridemia

By

In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.

Ezetimibe Plus Statin Therapy Yields Greater Cost-Savings vs Evolocumab

Ezetimibe Plus Statin Therapy Yields Greater Cost-Savings vs Evolocumab

By

Compared with evolocumab, the addition of ezetimibe to statin therapy is a major cost-saving strategy for preventing cardiovascular (CV) death in patients with T2D and an established CV disease.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Therapy Examined

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Therapy Examined

By

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

Predictors of Statin Discontinuation Among Older Adults

Predictors of Statin Discontinuation Among Older Adults

First-year nonadherence and discontinuation are high among older adults prescribed statins.

LDL-C Testing Associated With Lower Achieved LDL-C Levels

LDL-C Testing Associated With Lower Achieved LDL-C Levels

By

Investigators sought to determine whether clinician lipid testing practices were consistent with ACC/AHA 2013 recommended testing guidelines for LDL cholesterol.

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

By

Skin disorders, particularly those with known inflammatory mechanisms, may be considered potential early markers for the development of insulin resistance leading to metabolic syndrome, type 2 diabetes, and cardiovascular disease.

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

By

Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

By

Hyperglycemia, obesity, and hypertriglyceridemia are negatively related to cardiovascular autonomic neuropathy indices.

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

By

Repatha is a proprotein convertase subtilisin/kexin type 9 inhibitor.

Liraglutide Labeling Updated With Cardiovascular Safety Data

Liraglutide Labeling Updated With Cardiovascular Safety Data

By

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

By

In multivariable models, associations were observed between cardiovascular risk factors and cerebrovascular morphology, as well as white matter hyperintensity count.

CT Abdominal Aortic Calcification Score Predicts CV Event Risk

CT Abdominal Aortic Calcification Score Predicts CV Event Risk

A computed tomography (CT)-based abdominal aortic calcification (AAC) score is a strong predictor of future cardiovascular events in asymptomatic patients.

PCSK9 Inhibitor Tolerability Examined in Patients With Self-Reported Statin Intolerance

PCSK9 Inhibitor Tolerability Examined in Patients With Self-Reported Statin Intolerance

By

The study utilized patient-reported side effects to determine the tolerability of the PCSK9 inhibitors evolocumab and alirocumab.

Heritability of BMI Stronger in Obesogenic Environments

Heritability of BMI Stronger in Obesogenic Environments

By

Heritability of BMI was significantly higher in children living in high-risk obesogenic environments compared with those living in low-risk environments.

High Variability in Metabolic Parameters May Predict All-Cause Mortality

High Variability in Metabolic Parameters May Predict All-Cause Mortality

By

High variability of fasting blood glucose and total cholesterol levels, systolic blood pressure, and BMI may be an independent predictor of cardiovascular events.

Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy

Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy

By

Supplementation with coenzyme Q10 may be an effective approach for managing statin-induced myopathy.

Significant Mortality Reduction With Empagliflozin in T2D and Established CVD

Significant Mortality Reduction With Empagliflozin in T2D and Established CVD

By

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Lorcaserin Decreases Incident Diabetes Risk in Overweight Patients

Lorcaserin Decreases Incident Diabetes Risk in Overweight Patients

Lorcaserin reduces the risk for diabetes in obese or overweight patients with prediabetes or without diabetes and reduces HbA1c among those with diabetes.

Atopic Dermatitis Likely Not Associated With Cardiometabolic Disease

Atopic Dermatitis Likely Not Associated With Cardiometabolic Disease

By

Atopic dermatitis was not found to be an independent risk factor for cardiometabolic disease in this meta-analysis.

Sign Up for Free e-Newsletters